Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Bernd Hertenstein"'
Autor:
Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Gerald Wulf, Helmut Salih, Michael Lübbert, Michael W. M. Kühn, Thomas Schroeder, Hans Salwender, Katharina Götze, Jörg Westermann, Lars Fransecky, Karin Mayer, Bernd Hertenstein, Mark Ringhoffer, Hans-Joachim Tischler, Sigrid Machherndl-Spandl, Anika Schrade, Peter Paschka, Verena I. Gaidzik, Frauke Theis, Felicitas Thol, Michael Heuser, Richard F. Schlenk, Lars Bullinger, Maral Saadati, Axel Benner, Richard Larson, Richard Stone, Konstanze Döhner, Arnold Ganser
Publikováno v:
Blood Advances. 6:5345-5355
We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year midosta urin
Autor:
Thomas Schroeder, Hartmut Döhner, Heinz A. Horst, Arnold Ganser, Nadezda Basara, Julia Krzykalla, Karin Mayer, Axel Benner, Uwe M. Martens, Martin Bentz, Michael Lübbert, Peter Paschka, Thomas Kindler, Richard F. Schlenk, Michael Girschikofsky, Michael Heuser, Gerald Wulf, Elisabeth Koller, Katharina Götze, Richard Greil, Bernd Hertenstein, Felicitas Thol, Jürgen Krauter, Daniela Weber, David Nachbaur, Claudia Leis, Jan Schleicher, Walter Fiedler, Maisun Abu Samra, Konstanze Döhner, Silke Kapp-Schwoerer, Mohammed Wattad, Verena I. Gaidzik
Publikováno v:
Journal of Clinical Oncology
PURPOSE High CD33 expression in acute myeloid leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (GO) in this AML entity. We conducted a randomized trial to evaluate GO in combination with intensive indu
Autor:
Daphne Mytilineos, Chrysanthi Tsamadou, Christine Neuchel, Uwe Platzbecker, Donald Bunjes, Natalie Schub, Eva Wagner-Drouet, Gerald Wulf, Nicolaus Kröger, Niels Murawski, Hermann Einsele, Kerstin Schaefer-Eckart, Sebastian Freitag, Jochen Casper, Martin Kaufmann, Mareike Dürholt, Bernd Hertenstein, Stefan Klein, Mark Ringhoffer, Carlheinz R. Mueller, Sandra Frank, Hubert Schrezenmeier, Daniel Fuerst, Joannis Mytilineos
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology, Vol 11 (2021)
T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. W
Autor:
Hans Theodor Eich, Andreas Engert, Bernd Hertenstein, Felicitas Hitz, Walter E. Aulitzky, Peter Borchmann, Harald Stein, Michael Fuchs, Hans-Joachim Beck, Martin Bentz, Markus Dietlein, Julia Meissner, Max S. Topp, Helen Goergen, Ina Buehnen, Dennis A. Eichenauer, Carsten Kobe, Richard Greil, Jana Markova, Thomas Pabst, Wolfgang Willenbacher, Alden A. Moccia, Christian Baues, Martin Soekler, Helmut Ostermann, Volker Diehl, Georg Maschmeyer, Wolf-Dieter Ludwig, Dagmar Kühnhardt, Ulrich Keller, Tom Vieler, Stefanie Kreissl, Michaela Feuring-Buske, Josée M. Zijlstra
Publikováno v:
German Hodgkin Study Group 2021, ' PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial ', Lancet haematology, vol. 8, no. 6, pp. e398-e409 . https://doi.org/10.1016/S2352-3026(21)00101-0
Lancet haematology, 8(6), e398-e409. Lancet Publishing Group
Lancet haematology, 8(6), e398-e409. Lancet Publishing Group
Summary Background The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the trea
Autor:
Heinz Dürk, Arnold Ganser, Jan Rekowski, Andreas Hertel, Bernd Hertenstein, Lars Kurch, Matthias Sandmann, Winfried Brenner, Christiane Kreisel-Büstgens, Christiane Franzius, Wolfram Klapper, Matthias Weckesser, Aristoteles Giagounidis, Martin Freesmeyer, Thomas Krohn, Volker Runde, Dirk Behringer, Michael Heike, Stefan P. Müller, Frank Kroschinsky, Regina Moeller, Rolf Larisch, Hubertus Hautzel, Christine Schmitz, Gerhard Heil, Rolf M. Mesters, Ulrich Dührsen, Karl-Heinz Jöckel, Ferras Alashkar, Helga Bernhard, Dietmar Wacker, Uwe M. Martens, Stefan Mahlmann, Stefan Wilop, Jörg Kotzerke, Ronald Boellaard, Paul La Rosée, Gabriele Prange-Krex, Andreas Hüttmann, Heinz Gert Hoeffkes, Uwe Haberkorn, Guido Trenn, Dieter Hoelzer, Marcus Brinkmann, Frank M. Bengel
Publikováno v:
Schmitz, C, Rekowski, J, Müller, S P, Hertenstein, B, Franzius, C, Ganser, A, Bengel, F M, Kroschinsky, F, Kotzerke, J, La Rosée, P, Freesmeyer, M, Hoeffkes, H G, Hertel, A, Behringer, D, Mesters, R, Weckesser, M, Mahlmann, S, Haberkorn, U, Martens, U, Prange-Krex, G, Brenner, W, Giagounidis, A, Moeller, R, Runde, V, Sandmann, M, Hautzel, H, Wilop, S, Krohn, T, Dürk, H, Heike, M, Alashkar, F, Brinkmann, M, Trenn, G, Wacker, D, Kreisel-Büstgens, C, Bernhard, H, Heil, G, Larisch, R, Kurch, L, Jöckel, K H, Hoelzer, D, Klapper, W, Boellaard, R, Dührsen, U & Hüttmann, A 2020, ' Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma : A subgroup analysis of the PETAL trial ', Hematological Oncology, vol. 38, no. 3, pp. 244-256 . https://doi.org/10.1002/hon.2697
Hematological Oncology, 38(3), 244-256. John Wiley and Sons Ltd
Hematological Oncology, 38(3), 244-256. John Wiley and Sons Ltd
The prospective randomized Positron Emission Tomography (PET)-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial was designed to test the ability of interim PET (iPET) to direct therapy. As reported previously, outcome remained unaffect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099b8783f9b6d6dc0cff5a6c834fda48
https://research.vumc.nl/en/publications/15e83158-ea3b-4feb-ba8a-34400272cd82
https://research.vumc.nl/en/publications/15e83158-ea3b-4feb-ba8a-34400272cd82
Autor:
Katharina Götze, Thomas Heinicke, Arnold Ganser, M. Wattad, Thomas Kindler, Michael Girschikofsky, K Döhner, Gudrun Göhring, Gerald Wulf, Peter Brossart, Bernd Hertenstein, Cornelia Rudolph, Peter Paschka, Verena I. Gaidzik, Richard F. Schlenk, Heinz-August Horst, Daniela Weber, Felicitas Thol, S Erhardt, Michael Heuser, Helmut R. Salih, Hartmut Döhner, Michael Lübbert, Joerg Westermann, Veronica Teleanu, Gabriele Nagel, Walter Fiedler, Jürgen Krauter, Andrea Kündgen, Hans-Günter Derigs, Ella Fromm, Doris Kraemer, Lars Bullinger
Publikováno v:
Annals of Hematology
We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within t
Autor:
Erika Borlenghi, Arnold Ganser, Christian Thiede, Hartmut Döhner, Roberto Cairoli, Mohammed Wattad, Norbert Schmitz, Agostino Cortelezzi, Alfonso Maria D'Arco, Massimo Breccia, Franco Mandelli, Richard F. Schlenk, Mariadomenica Divona, Marco Sborgia, Francesco Albano, Laura Cicconi, Enrico Maria Pogliani, Konstanze Döhner, Claudio Fozza, Giuseppe Avvisati, Francesco Lo-Coco, Michael Lübbert, Felicetto Ferrara, Sergio Amadori, Walter Fiedler, Francesco Fabbiano, Bernd Hertenstein, Helmut R. Salih, Lorella Melillo, Uwe Platzbecker, Alessandro Rambaldi, Giorgio La Nasa, Christian Brandts, Nicola Di Renzo, Christoph Röllig, Hartmut Link, Marco Vignetti, Francesca Paoloni, Eros Di Bona, Fabio Efficace, Peter Brossart, Chiara Frairia, Paola Fazi, Gerhard Ehninger, Mathias Hänel
Publikováno v:
Journal of Clinical Oncology. 35:605-612
Purpose The initial results of the APL0406 trial showed that the combination of all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-
Autor:
Bernd Hertenstein, M. Wattad, Jürgen Krauter, Peter Paschka, Gesine Bug, Gerhard Heil, Lars Bullinger, Jana Fabisch, Walter Fiedler, Verena I. Gaidzik, Hartmut Döhner, Sabrina Klesse, Arnold Ganser, Hartmut Kirchner, Brigitte Schlegelberger, Felicitas Thol, Alessandro Liebich, Arnold Kloos, Michael Heuser, Hubert Serve, Gudrun Göhring, Razif Gabdoulline, Anuhar Chaturvedi, Doris Kraemer, Richard F. Schlenk, L Köhler, Martin Wichmann, Konstanze Döhner, Michael Lübbert
Publikováno v:
Leukemia
We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment. Diagnostic, complete remiss
Autor:
Bernd Hertenstein, Lars Kurch, Roland Schroers, Andreas Hüttmann, Thomas Krohn, Georg Maschmeyer, Ariane Dienst, Heinz-Gert Höffkes, Ingo Brink, Gabriele Prange-Krex, Aruna Raghavachar, Alfred Klein, Christine Schmitz, Andreas Schwarzer, Gabriele Pöpperl, Wolfram Klapper, Andreas Hertel, Martin Griesshammer, Stefan P. Müller, Matthias Weckesser, Ralph Naumann, Heike Steiniger, Matthias Grube, Wolfgang Römer, Dieter Hoelzer, Marcus Brinkmann, Jan Dürig, Christiane Franzius, Thomas Südhoff, Frank M. Bengel, Holger Nückel, Claudia Ose, Ulrich Dührsen, Karl-Heinz Jöckel, Jan Rekowski, Thomas Höhler, Aristoteles Giagounidis, Arnold Ganser, Dennis Hahn, Paul La Rosée, Helga Bernhard, Jörg Kotzerke, Frank Kroschinsky, Hubertus Hautzel, Dirk Behringer, Jochen Schütte, Tobias Gaska, Rolf M. Mesters, Ferras Alashkar, Jens Holzinger, Stefan Wilop, Jörg Marienhagen, Martin Freesmeyer
Standard first-line treatment of aggressive B cell lymphoma comprises six or eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus eight doses of rituximab (R). Whether adding two doses of rituximab to six cycles of R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b0a4c5c1983a3867477b6ca9f0e2df7
https://www.ncbi.nlm.nih.gov/pubmed/30610279
https://www.ncbi.nlm.nih.gov/pubmed/30610279
Autor:
Marco Sborgia, Marco Vignetti, Massimo Breccia, Fabio Efficace, Roberto Cairoli, Hartmut Link, Uwe Platzbecker, Norbert Schmitz, Ombretta Annibali, Agostino Cortelezzi, Francesca Paoloni, Eros Di Bona, Nicola Di Renzo, Alfonso Maria D'Arco, Lorella Melillo, Francesco Lo-Coco, Peter Brossart, Felicetto Ferrara, Chiara Frairia, Franco Mandelli, Christoph Röllig, Laura Cicconi, Claudio Fozza, Konstanze Döhner, Walter Fiedler, Bernd Hertenstein, Francesco Fabbiano, Richard F. Schlenk, Mariadomenica Divona, Francesco Albano, Mohammed Wattad, Maria Teresa Voso, Christian Thiede, Christian Brandts, Paola Fazi, Gerhard Ehninger, Mathias Hänel, Sergio Amadori, Alessandro Rambaldi, Giorgio La Nasa, Helmut R. Salih, Hartmut Döhner, Michael Lübbert, Giuseppe Avvisati, Arnold Ganser, Erika Borlenghi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::968a365df311f41af4214e369b02e012
http://hdl.handle.net/2108/226570
http://hdl.handle.net/2108/226570